Detalhe da pesquisa
1.
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
JAMA
; 331(5): 408-416, 2024 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319331
2.
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
MMWR Morb Mortal Wkly Rep
; 71(11): 422-428, 2022 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298453
3.
Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
MMWR Morb Mortal Wkly Rep
; 70(5152): 1761-1765, 2021 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34968373